This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
cidp
CIDP
CIDP (chronic inflammatory demyelinating polyneuropathy) is immune-mediated PNS demyelination lasting >8 weeks; anti-NF155/CNTN1 IgG4 define subtypes; IVIG and corticosteroids first-line; efgartigimod (FcRn inhibitor; FDA Jun 2024) and inebilizumab (anti-CD19) are new options.
Entry Metadata
| Field | Value |
|---|---|
| ID | cidp |
| Name | CIDP |
| Status | draft |
| Last reviewed | 2026-06-07 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(1):1-9. · PubMed 20433600
- Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study). Lancet Neurol. 2008;7(2):136-144. · PubMed 18178525
- van den Bergh PYK, van Doorn PA, Hadden RDM, et al. Efgartigimod alfa and hyaluronidase-qvfc in CIDP (ADHERE). N Engl J Med. 2023;390(3):219-232. · PubMed 38197812
- Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: 2023 update. Eur J Neurol. 2023;30(10):2976-3020. · PubMed 37382198